Delineation of proapoptotic signaling of anthracene-shelled M2L4 metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines Rositsa MihaylovaAnife AhmedovaNikolay Danchev PRECLINICAL STUDIES 08 February 2019 Pages: 1117 - 1126
LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/ FOXP1 axis in lung cancer Ansheng WangChengling ZhaoKangwu Wang PRECLINICAL STUDIES Open access 08 February 2019 Pages: 1127 - 1134
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma Sonia BrunFiras BassissiPhilipe Halfon PRECLINICAL STUDIES 19 February 2019 Pages: 1135 - 1145
Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer Juan TangNa WangSheng Lin PRECLINICAL STUDIES 21 February 2019 Pages: 1146 - 1157
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage Hyun-Cheol KangEui Kyu ChieEunSook Ma PRECLINICAL STUDIES 22 February 2019 Pages: 1158 - 1165
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer Xiaoli LiuWei WangWenchu Lin PRECLINICAL STUDIES 02 March 2019 Pages: 1166 - 1176
Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion Fa-an MiaoKun ChuYong-ping You PRECLINICAL STUDIES 07 March 2019 Pages: 1177 - 1186
Novel palladium (II) complexes with tetradentate thiosemicarbazones. Synthesis, characterization, in vitro cytotoxicity and xanthine oxidase inhibition Dilşad ÖzerkanOnur ErtikBahri Ülküseven PRECLINICAL STUDIES 14 March 2019 Pages: 1187 - 1197
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials Dylan J. MartiniYuan LiuMehmet Asim Bilen PHASE I STUDIES 06 February 2019 Pages: 1198 - 1206
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations Makoto NishioHaruyasu MurakamiTomohide Tamura PHASE I STUDIES Open access 21 February 2019 Pages: 1207 - 1217
Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors Fei TangEleftheria TsakalozouMarkos Leggas PHASE I STUDIES 28 February 2019 Pages: 1218 - 1230
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer Haris ZahoorMaria C. MirJorge A. Garcia PHASE II STUDIES 24 June 2019 Pages: 1231 - 1238
A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component Inkeun ParkHyo Jin LeeJae Lyun Lee PHASE II STUDIES 24 June 2019 Pages: 1239 - 1246
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia Kara D. CapriottiMilan AnadkatMario Lacouture PHASE II STUDIES 26 June 2019 Pages: 1247 - 1256
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab Hayato KawachiDaichi FujimotoKeisuke Tomii PHASE III STUDIES 01 April 2019 Pages: 1257 - 1265
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) Motohiro TamiyaAkihiro TamiyaDaichi Fujimoto PHASE III STUDIES 07 August 2019 Pages: 1266 - 1273
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Giandomenico RovielloNavid SohbaniMaria Grazia Rodriquenz REVIEW 16 March 2019 Pages: 1274 - 1288
Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma G. BeinseA. HulinBenoit Rousseau SHORT REPORT 26 February 2019 Pages: 1289 - 1291
Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells Adam HermawanRatna Asmah SusidartiEdy Meiyanto SHORT REPORT 30 March 2019 Pages: 1292 - 1299
Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells Jian-Ning YaoXue-Xiu ZhangLian-Feng Zhang SHORT REPORT 30 March 2019 Pages: 1300 - 1308
Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway Piming ZhaoAna E. AguilarJulie D. Saba Correction 29 April 2019 Pages: 1309 - 1309
Correction to: Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors Preeti RoyJasmine GeorgeYogeshwer Shukla Correction 07 August 2019 Pages: 1310 - 1311